Participation in a clinical trial influences the future management of patients with gastro-oesophageal reflux disease in general practice
Version of Record online: 12 SEP 2006
Alimentary Pharmacology & Therapeutics
Volume 24, Issue 7, pages 1117–1125, October 2006
How to Cite
MEINECHE-SCHMIDT, V., HVENEGAARD, A. and JUHL, H. H. (2006), Participation in a clinical trial influences the future management of patients with gastro-oesophageal reflux disease in general practice. Alimentary Pharmacology & Therapeutics, 24: 1117–1125. doi: 10.1111/j.1365-2036.2006.03046.x
- Issue online: 12 SEP 2006
- Version of Record online: 12 SEP 2006
- Publication data Submitted 25 March 2006 First decision 9 April 2006 Resubmitted 23 June 2006 Accepted 26 June 2006
- 2Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomised, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27–34., , , et al.Direct Link:
- 5Systematic review: The efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2205; 21: 1299–312., , , .
- 6Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 18: CD003245., , , .
- 9A study of general practitioners’ reason for changing their prescribing behaviour. BMJ 1996; 12: 949–52., , .